Interleukin-6 in idiopathic multicentric Castleman’s disease after long-term tocilizumab

Mitsuhiro Akiyama; Hidekata Yasuoka; Tsutomu Takeuchi

doi:10.1007/s00277-017-3111-x

Interleukin-6 in idiopathic multicentric Castleman’s disease after long-term tocilizumab

Mitsuhiro Akiyama, Hidekata Yasuoka, Tsutomu Takeuchi

研究成果: ジャーナルへの寄稿 › Letter › 査読

本文言語	英語
ページ（範囲）	2117-2119
ページ数	3
ジャーナル	Annals of Hematology
巻	96
号	12
DOI	https://doi.org/10.1007/s00277-017-3111-x
出版ステータス	出版済み - 01-12-2017
外部発表	はい

All Science Journal Classification (ASJC) codes

血液学

文献へのアクセス

10.1007/s00277-017-3111-x

他のファイルとリンク

引用スタイル

@article{c15dd49d7bcc4afbbd33dc0b010d7e16,

title = "Interleukin-6 in idiopathic multicentric Castleman{\textquoteright}s disease after long-term tocilizumab",

author = "Mitsuhiro Akiyama and Hidekata Yasuoka and Tsutomu Takeuchi",

note = "Funding Information: Conflict of interest MA has received consultancies, speaking fees, and honoraria from Asahi Kasei Co., Cure Grades Co., and Eisai Co., Ltd., and received research grant from Mitsubishi Tanabe Pharma Co. T.T. has received consulting fees, speaking fees, and/or honoraria from Pfizer Japan, Mitsubishi Tanabe Pharma, Eisai, Astellas Pharma and UCB (less than $10,000 each) and from Chugai Pharmaceutical, Bristol-Myers K.K., Daiichi Sankyo, AbbVie, Janssen Pharmaceutical K.K., Pfizer Japan, Asahi Kasei Pharma, Takeda Pharmaceutical, AstraZeneca K.K., Eli Lilly Japan K.K., and Novartis Pharma K.K. (more than $10,000 each). Funding Information: We thank Mrs. Keiko Yoshimoto for the assistance of data collection. This study was approved by the institutional ethics committee of Keio University School of Medicine. Informed consent was obtained from all the patients and healthy donors. MA has received consultancies, speaking fees, and honoraria from Asahi Kasei Co., Cure Grades Co., and Eisai Co., Ltd., and received research grant from Mitsubishi Tanabe Pharma Co. T.T. has received consulting fees, speaking fees, and/or honoraria from Pfizer Japan, Mitsubishi Tanabe Pharma, Eisai, Astellas Pharma and UCB (less than $10,000 each) and from Chugai Pharmaceutical, Bristol-Myers K.K., Daiichi Sankyo, AbbVie, Janssen Pharmaceutical K.K., Pfizer Japan, Asahi Kasei Pharma, Takeda Pharmaceutical, AstraZeneca K.K., Eli Lilly Japan K.K., and Novartis Pharma K.K. (more than $10,000 each).",

year = "2017",

month = dec,

day = "1",

doi = "10.1007/s00277-017-3111-x",

language = "English",

volume = "96",

pages = "2117--2119",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "12",

}

TY - JOUR

T1 - Interleukin-6 in idiopathic multicentric Castleman’s disease after long-term tocilizumab

AU - Akiyama, Mitsuhiro

AU - Yasuoka, Hidekata

AU - Takeuchi, Tsutomu

N1 - Funding Information: Conflict of interest MA has received consultancies, speaking fees, and honoraria from Asahi Kasei Co., Cure Grades Co., and Eisai Co., Ltd., and received research grant from Mitsubishi Tanabe Pharma Co. T.T. has received consulting fees, speaking fees, and/or honoraria from Pfizer Japan, Mitsubishi Tanabe Pharma, Eisai, Astellas Pharma and UCB (less than $10,000 each) and from Chugai Pharmaceutical, Bristol-Myers K.K., Daiichi Sankyo, AbbVie, Janssen Pharmaceutical K.K., Pfizer Japan, Asahi Kasei Pharma, Takeda Pharmaceutical, AstraZeneca K.K., Eli Lilly Japan K.K., and Novartis Pharma K.K. (more than $10,000 each). Funding Information: We thank Mrs. Keiko Yoshimoto for the assistance of data collection. This study was approved by the institutional ethics committee of Keio University School of Medicine. Informed consent was obtained from all the patients and healthy donors. MA has received consultancies, speaking fees, and honoraria from Asahi Kasei Co., Cure Grades Co., and Eisai Co., Ltd., and received research grant from Mitsubishi Tanabe Pharma Co. T.T. has received consulting fees, speaking fees, and/or honoraria from Pfizer Japan, Mitsubishi Tanabe Pharma, Eisai, Astellas Pharma and UCB (less than $10,000 each) and from Chugai Pharmaceutical, Bristol-Myers K.K., Daiichi Sankyo, AbbVie, Janssen Pharmaceutical K.K., Pfizer Japan, Asahi Kasei Pharma, Takeda Pharmaceutical, AstraZeneca K.K., Eli Lilly Japan K.K., and Novartis Pharma K.K. (more than $10,000 each).

PY - 2017/12/1

Y1 - 2017/12/1

UR - http://www.scopus.com/inward/record.url?scp=85028743843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028743843&partnerID=8YFLogxK

U2 - 10.1007/s00277-017-3111-x

DO - 10.1007/s00277-017-3111-x

M3 - Letter

C2 - 28861599

AN - SCOPUS:85028743843

SN - 0939-5555

VL - 96

SP - 2117

EP - 2119

JO - Annals of Hematology

JF - Annals of Hematology

IS - 12

ER -